What is the Rossari Biotech PE ratio today?
Rossari Biotech's PE ratio is 14.5 at the 30 October 2026 close (₹399.25 a share): a market capitalisation of ₹2,212 crore divided by consolidated net profit of ₹153 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹149 crore) it is 14.8.
Is Rossari Biotech debt free?
No. Rossari Biotech had borrowings of ₹362 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.26. Its cash and current investments were ₹141 crore, so its net debt was ₹221 crore.
What is the Rossari Biotech debt to equity ratio?
Rossari Biotech's debt-to-equity ratio was 0.26 on 30 September 2026: borrowings of ₹362 crore against total equity of ₹1,408 crore. A year earlier, on 30 September 2025, it was 0.26.
What is the Rossari Biotech PB ratio (price to book value)?
Rossari Biotech's price-to-book (PB) ratio is 1.57 at the 30 October 2026 close: a market capitalisation of ₹2,212 crore divided by shareholders' equity (book value) of ₹1,408 crore on 30 September 2026. That is a book value of ₹254.10 per share against a share price of ₹399.25.
What is the Rossari Biotech net worth?
Rossari Biotech's net worth — shareholders' equity in its consolidated balance sheet — was ₹1,408 crore on 30 September 2026, up 12.5% from ₹1,251 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹2,212 crore at the 30 October 2026 close.
What is the Rossari Biotech ROE and ROCE?
In FY26, Rossari Biotech's return on equity (ROE) was 11.9% and its return on capital employed (ROCE) was 14.5%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 12.2% and ROCE 15.8%.
What is the Rossari Biotech market cap?
Rossari Biotech's market capitalisation was ₹2,212 crore at the 30 October 2026 close: 5.54 crore shares at ₹399.25 each.
What is the Rossari Biotech EPS?
Rossari Biotech's basic earnings per share (EPS) were ₹26.95 in FY26, against ₹24.66 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹27.58.
What is the Rossari Biotech dividend in 2026 and its record date?
In 2026, Rossari Biotech has declared one dividend: ₹0.50 with record date 10 July 2026.
What is the Rossari Biotech book value per share?
Rossari Biotech's book value per share was ₹254.10 on 30 September 2026: shareholders' equity of ₹1,408 crore divided by the 5.54 crore shares in issue, up 12.4% from ₹226.05 a year earlier. The share price at the 30 October 2026 close was ₹399.25.
What is the Rossari Biotech dividend yield?
Rossari Biotech's dividend yield is 0.13% at the 30 October 2026 close: dividends of ₹0.50 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹399.25. They were ₹0.50 on 10 July 2026.
What is the Rossari Biotech revenue and profit in FY26?
In FY26 (April 2025–March 2026), Rossari Biotech's consolidated net profit was ₹149 crore, up 9.4% from ₹136 crore in FY25, on revenue from operations of ₹2,396 crore (up 15.2%). Over three years, from FY23, net profit was up 39.1%.
What is the Rossari Biotech promoter holding?
Promoters held 68.14% of Rossari Biotech on 30 September 2026, unchanged from the previous quarter and down 0.03 percentage points from 68.17% a year earlier, according to the shareholding pattern filed with NSE.
What is the Rossari Biotech free cash flow?
In FY26, Rossari Biotech generated ₹65.1 crore of cash from operations and spent ₹265 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹200 crore. In FY25 it was −₹21.1 crore.
What are the Rossari Biotech latest quarterly results?
Rossari Biotech's latest results are for Q2 FY27 (July–September 2026): consolidated net profit ₹38.9 crore, up 5.5% from ₹36.9 crore in Q2 FY26; revenue from operations ₹698 crore, up 19.0% year on year.
What is the Rossari Biotech shareholding pattern?
On 30 September 2026, Rossari Biotech's shares were held by promoters 68.14%, foreign portfolio investors (FII/FPI) 1.84%, domestic institutions (DII) 14.19% (including mutual funds at 9.11%) and retail and other non-institutional investors 15.83%. Over the year, FII holding was down 0.85 percentage points from 2.69% and DII holding was down 3.99 percentage points from 18.18%.
How does the Rossari Biotech PE ratio compare with its peers?
At the 30 October 2026 closing prices, on FY26 net profit, Rossari Biotech's PE ratio is 14.8, the lowest of the four: NOCIL 41.2, Himadri Speciality Chemical 34.2 and Navin Fluorine International 67.1, a peer average of 47.5. Each is the company's market capitalisation at that price divided by its FY26 net profit.
Rossari Biotech vs NOCIL: how do they compare?
In FY26, Rossari Biotech earned net profit of ₹149 crore on revenue of ₹2,396 crore, against ₹55.6 crore on ₹1,303 crore for NOCIL. Rossari Biotech's operating margin was 8.6% (NOCIL 3.5%) and its return on equity 11.9% (NOCIL 3.2%). At the 30 October 2026 close, Rossari Biotech's market capitalisation was ₹2,212 crore against ₹2,290 crore for NOCIL, and its PE ratio on FY26 profit 14.8 against 41.2.
When are the Rossari Biotech next results?
Rossari Biotech has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
How does Rossari Biotech compare with its peers?
On FY26 consolidated figures, against NOCIL, Himadri Speciality Chemical and Navin Fluorine International: Rossari Biotech's operating margin of 8.6% is the third highest of the four (NOCIL 3.5%, Himadri Speciality Chemical 19.2%, Navin Fluorine International 28.1%; peer average 16.9%); its return on equity of 11.9% is the third highest of the four (NOCIL 3.2%, Himadri Speciality Chemical 17.8%, Navin Fluorine International 20.1%; peer average 13.7%); its revenue growth over three years of 13.1% a year is the second highest of the four (NOCIL −6.9% a year, Himadri Speciality Chemical 3.8% a year, Navin Fluorine International 16.8% a year; peer average 4.6% a year).
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
